Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy.

You Y, Perkins A, Cisternas P, Muñoz B, Taylor X, You Y, Garringer HJ, Oblak AL, Atwood BK, Vidal R, Lasagna-Reeves CA.

Acta Neuropathol Commun. 2019 Feb 26;7(1):26. doi: 10.1186/s40478-019-0680-z.

2.

TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy.

Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, Landreth GE, Lamb BT.

Mol Neurodegener. 2017 Oct 16;12(1):74. doi: 10.1186/s13024-017-0216-6.

3.

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau.

Rousseaux MW, de Haro M, Lasagna-Reeves CA, De Maio A, Park J, Jafar-Nejad P, Al-Ramahi I, Sharma A, See L, Lu N, Vilanova-Velez L, Klisch TJ, Westbrook TF, Troncoso JC, Botas J, Zoghbi HY.

Elife. 2016 Oct 25;5. pii: e19809. doi: 10.7554/eLife.19809.

4.

Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.

Lasagna-Reeves CA, de Haro M, Hao S, Park J, Rousseaux MW, Al-Ramahi I, Jafar-Nejad P, Vilanova-Velez L, See L, De Maio A, Nitschke L, Wu Z, Troncoso JC, Westbrook TF, Tang J, Botas J, Zoghbi HY.

Neuron. 2016 Oct 19;92(2):407-418. doi: 10.1016/j.neuron.2016.09.022. Epub 2016 Oct 6.

5.

Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes.

Lasagna-Reeves CA, Rousseaux MW, Guerrero-Munoz MJ, Vilanova-Velez L, Park J, See L, Jafar-Nejad P, Richman R, Orr HT, Kayed R, Zoghbi HY.

Elife. 2015 Dec 17;4. pii: e10891. doi: 10.7554/eLife.10891.

6.

A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1.

Lasagna-Reeves CA, Rousseaux MW, Guerrero-Muñoz MJ, Park J, Jafar-Nejad P, Richman R, Lu N, Sengupta U, Litvinchuk A, Orr HT, Kayed R, Zoghbi HY.

Elife. 2015 May 19;4. doi: 10.7554/eLife.07558.

7.

Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.

Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, Krishnamurthy S, Farhed M, Jackson GR, Kayed R.

Biol Psychiatry. 2015 Nov 15;78(10):672-83. doi: 10.1016/j.biopsych.2014.12.019. Epub 2015 Jan 9.

PMID:
25676491
8.

Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, Ahmad Y, Jackson GR, Kayed R.

Neurobiol Dis. 2014 Nov;71:14-23. doi: 10.1016/j.nbd.2014.08.008. Epub 2014 Aug 15.

PMID:
25134727
9.

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Muñoz MJ, Troncoso J, Kayed R.

Acta Neuropathol Commun. 2014 Jun 14;2:73. doi: 10.1186/2051-5960-2-73.

10.

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes.

Lasagna-Reeves CA, Sengupta U, Castillo-Carranza D, Gerson JE, Guerrero-Munoz M, Troncoso JC, Jackson GR, Kayed R.

Acta Neuropathol Commun. 2014 May 29;2:56. doi: 10.1186/2051-5960-2-56.

11.

Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.

Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R.

J Neurosci. 2014 Mar 19;34(12):4260-72. doi: 10.1523/JNEUROSCI.3192-13.2014.

12.

Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.

Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R.

J Alzheimers Dis. 2014;40 Suppl 1:S97-S111. doi: 10.3233/JAD-132477.

PMID:
24603946
13.

Tau aggregates as immunotherapeutic targets.

Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R.

Front Biosci (Schol Ed). 2013 Jan 1;5:426-38. Review.

PMID:
23277060
14.

Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.

Lasagna-Reeves CA, Clos AL, Castillo-Carranza D, Sengupta U, Guerrero-Muñoz M, Kelly B, Wagner R, Kayed R.

Biochem Biophys Res Commun. 2013 Jan 18;430(3):963-8. doi: 10.1016/j.bbrc.2012.11.130. Epub 2012 Dec 19.

PMID:
23261448
15.

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau.

Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R.

Sci Rep. 2012;2:700. doi: 10.1038/srep00700. Epub 2012 Oct 3.

16.

Molecular mechanisms of amyloid oligomers toxicity.

Kayed R, Lasagna-Reeves CA.

J Alzheimers Dis. 2013;33 Suppl 1:S67-78. doi: 10.3233/JAD-2012-129001. Review.

PMID:
22531422
17.

Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis.

Clos AL, Kayed R, Lasagna-Reeves CA.

Front Neurol. 2012 Jan 20;3:5. doi: 10.3389/fneur.2012.00005. eCollection 2012.

18.

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R.

FASEB J. 2012 May;26(5):1946-59. doi: 10.1096/fj.11-199851. Epub 2012 Jan 17.

19.

Astrocytes contain amyloid-β annular protofibrils in Alzheimer's disease brains.

Lasagna-Reeves CA, Kayed R.

FEBS Lett. 2011 Oct 3;585(19):3052-7. doi: 10.1016/j.febslet.2011.08.027. Epub 2011 Aug 24.

20.

Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.

Clos AL, Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Jackson GR, Kelly B, Beachkofsky TM, Kayed R.

Br J Dermatol. 2011 Dec;165(6):1349-54. doi: 10.1111/j.1365-2133.2011.10508.x. Epub 2011 Oct 17.

PMID:
21729025

Supplemental Content

Loading ...
Support Center